CN103202821B - 一种骨化三醇软胶囊及其制备方法 - Google Patents
一种骨化三醇软胶囊及其制备方法 Download PDFInfo
- Publication number
- CN103202821B CN103202821B CN201310120522.0A CN201310120522A CN103202821B CN 103202821 B CN103202821 B CN 103202821B CN 201310120522 A CN201310120522 A CN 201310120522A CN 103202821 B CN103202821 B CN 103202821B
- Authority
- CN
- China
- Prior art keywords
- soft capsule
- calcitriol
- minutes
- capsule
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007901 soft capsule Substances 0.000 title claims abstract description 70
- 239000011612 calcitriol Substances 0.000 title claims abstract description 46
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 title claims abstract description 46
- 229960005084 calcitriol Drugs 0.000 title claims abstract description 45
- 235000020964 calcitriol Nutrition 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 40
- 239000000463 material Substances 0.000 claims abstract description 22
- 108010010803 Gelatin Proteins 0.000 claims abstract description 17
- 239000008273 gelatin Substances 0.000 claims abstract description 17
- 229920000159 gelatin Polymers 0.000 claims abstract description 17
- 235000019322 gelatine Nutrition 0.000 claims abstract description 17
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000003921 oil Substances 0.000 claims abstract description 11
- 239000007957 coemulsifier Substances 0.000 claims abstract description 10
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 10
- 239000002775 capsule Substances 0.000 claims description 20
- -1 polyoxyethylene Polymers 0.000 claims description 19
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 235000019198 oils Nutrition 0.000 claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 239000003292 glue Substances 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 238000005096 rolling process Methods 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 claims 2
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical group CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims 1
- 239000012467 final product Substances 0.000 claims 1
- 238000009413 insulation Methods 0.000 claims 1
- 238000007670 refining Methods 0.000 claims 1
- 238000004513 sizing Methods 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 2
- 238000007789 sealing Methods 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 description 17
- 235000011187 glycerol Nutrition 0.000 description 15
- 239000000243 solution Substances 0.000 description 12
- 239000004359 castor oil Substances 0.000 description 9
- 235000019438 castor oil Nutrition 0.000 description 9
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 235000019864 coconut oil Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 description 2
- 235000021318 Calcifediol Nutrition 0.000 description 2
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 2
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 2
- JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 201000006409 renal osteodystrophy Diseases 0.000 description 2
- 229950004959 sorbitan oleate Drugs 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- 239000003872 25-hydroxy-cholecalciferol Substances 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 208000029663 Hypophosphatemia Diseases 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 201000006035 X-linked dominant hypophosphatemic rickets Diseases 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 229960004361 calcifediol Drugs 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 208000011111 hypophosphatemic rickets Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000006078 pseudohypoparathyroidism Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000032349 type 2B vitamin D-dependent rickets Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
0天 | 1个月 | 2个月 | 3个月 | 4个月 | 5个月 | 6个月 | 7个月 | |
实施例1 | 9分钟 | 9分钟 | 9分钟 | 9分钟 | 10分钟 | 10分钟 | 10分钟 | 11分钟 |
实施例2 | 8分钟 | 8分钟 | 9分钟 | 9分钟 | 11分钟 | 11分钟 | 11分钟 | 12分钟 |
实施例3 | 8分钟 | 9分钟 | 9分钟 | 9分钟 | 9分钟 | 9分钟 | 10分钟 | 11分钟 |
实施例4 | 9分钟 | 9分钟 | 9分钟 | 10分钟 | 10分钟 | 10分钟 | 10分钟 | 11分钟 |
实施例5 | 9分钟 | 9分钟 | 9分钟 | 10分钟 | 10分钟 | 11分钟 | 11分钟 | 12分钟 |
市售 | 8分钟 | 9分钟 | 9分钟 | 9分钟 | 12分钟 | 14分钟 | 16分钟 | 16分钟 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310120522.0A CN103202821B (zh) | 2013-04-09 | 2013-04-09 | 一种骨化三醇软胶囊及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310120522.0A CN103202821B (zh) | 2013-04-09 | 2013-04-09 | 一种骨化三醇软胶囊及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103202821A CN103202821A (zh) | 2013-07-17 |
CN103202821B true CN103202821B (zh) | 2014-10-01 |
Family
ID=48750381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310120522.0A Active CN103202821B (zh) | 2013-04-09 | 2013-04-09 | 一种骨化三醇软胶囊及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103202821B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109260209B (zh) * | 2018-11-26 | 2021-07-13 | 正大制药(青岛)有限公司 | 一种骨化三醇软胶囊及其制备方法 |
CN109248156A (zh) * | 2018-11-27 | 2019-01-22 | 正大制药(青岛)有限公司 | 一种帕立骨化醇软胶囊 |
CN118304270B (zh) * | 2024-03-27 | 2025-03-07 | 青岛双鲸药业股份有限公司 | 一种维生素d滴剂及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4341774A (en) * | 1979-08-10 | 1982-07-27 | Chugai Seiyaku Kabushiki Kaisha | Method for suppressing abnormal rise in immunological function and agent useful therefor |
CN1371281A (zh) * | 1999-08-31 | 2002-09-25 | 中外制药株式会社 | 软胶囊剂 |
US6759396B1 (en) * | 1995-09-15 | 2004-07-06 | Centre International De Recherches Dermatalogiques Galderma (C.I.R.D.) Galderma | Compositions based on a synergistic mixture of at least one VDR ligand and a retinoid |
CN101810336A (zh) * | 2010-04-30 | 2010-08-25 | 广东仙乐制药有限公司 | 一种咀嚼性软胶囊及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6045516A (ja) * | 1983-08-02 | 1985-03-12 | Kureha Chem Ind Co Ltd | 1α―ヒドロキシビタミンD3類を含有することを特徴とする抗炎症解熱鎮痛剤 |
-
2013
- 2013-04-09 CN CN201310120522.0A patent/CN103202821B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4341774A (en) * | 1979-08-10 | 1982-07-27 | Chugai Seiyaku Kabushiki Kaisha | Method for suppressing abnormal rise in immunological function and agent useful therefor |
US6759396B1 (en) * | 1995-09-15 | 2004-07-06 | Centre International De Recherches Dermatalogiques Galderma (C.I.R.D.) Galderma | Compositions based on a synergistic mixture of at least one VDR ligand and a retinoid |
CN1371281A (zh) * | 1999-08-31 | 2002-09-25 | 中外制药株式会社 | 软胶囊剂 |
CN101810336A (zh) * | 2010-04-30 | 2010-08-25 | 广东仙乐制药有限公司 | 一种咀嚼性软胶囊及其制备方法 |
Non-Patent Citations (1)
Title |
---|
JP昭60-45516A 1985.03.12 |
Also Published As
Publication number | Publication date |
---|---|
CN103202821A (zh) | 2013-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2834900T3 (es) | Formulación de vitamina d de liberación modificada estabilizada y procedimiento de administración de la misma | |
CN104162168B (zh) | 一种稳定的帕立骨化醇药物组合物及其制备方法 | |
CN106265586A (zh) | 一种骨化三醇软胶囊制剂的制备方法 | |
CN113559314B (zh) | 用于糖尿病足溃疡的仿细胞外基质水凝胶敷料及制备方法 | |
CN103202821B (zh) | 一种骨化三醇软胶囊及其制备方法 | |
CN103536574A (zh) | 一种辅酶q10软胶囊及其制备方法 | |
CN105878208A (zh) | 一种淀粉基植物药用硬胶囊成型剂及其应用 | |
CN103394092B (zh) | 由结冷胶和氯化钙凝胶的羟丙甲纤维素肠溶空心胶囊 | |
CN105362253A (zh) | 一种新型远红外凝胶膏 | |
CN103877067B (zh) | 一种可控制崩解时限的空心胶囊及其制备方法 | |
CN102614111A (zh) | 氨基葡萄糖的凝胶剂及其制备方法 | |
CN104352475A (zh) | 一种米拉贝隆缓释片及其制备方法 | |
CN101632675A (zh) | 富马酸亚铁叶酸药物组合物及其脂质体固体制剂 | |
CN104434847A (zh) | 一种非诺贝酸胆碱缓释微丸及其制备方法 | |
CN107362151A (zh) | 一种骨化三醇液体硬胶囊剂及其制备方法、应用 | |
CN102370673A (zh) | 苏冰(速效救心)喷雾剂及其制备方法 | |
CN103417978B (zh) | 由结冷胶和柠檬酸钾凝胶的羟丙甲纤维素肠溶空心胶囊 | |
CN103315961A (zh) | 新藤黄酸自微乳制剂及其制备方法 | |
CN100544730C (zh) | 异甘草酸镁外用制剂及其制备方法和应用 | |
CN112156096B (zh) | 叶酸缓释组合物、缓释制剂及其应用 | |
CN101716135B (zh) | 大豆异黄酮固体分散体栓剂及其制备方法 | |
CN110279668A (zh) | 一种醋酸钙药物组合物及其制备方法和应用 | |
CN105361226B (zh) | 一种以鱼明胶为胶皮原料的软胶囊胶囊配方及制备方法 | |
CN108853167A (zh) | 一种含有壳聚糖的痔疮组合物、制备方法及其应用 | |
CN106580959A (zh) | 一种缓解急性缺血性脑卒中的丁苯酞尼群地平软胶囊 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 266000, unity Road, Qingdao economic and Technological Development Zone, Qingdao, Shandong 3601, China Applicant after: Qingdao Zhengda Haier Pharmaceutical Co.,Ltd. Address before: 266103 Haier Industrial Park, No. 1, Haier Road, Laoshan District, Shandong, Qingdao Applicant before: Qingdao Zhengda Haier Pharmaceutical Co.,Ltd. |
|
CB02 | Change of applicant information | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: 266000 3601 Tuen Road, Qingdao economic and Technological Development Zone, Qingdao, Shandong Patentee after: CP PHARMACEUTICAL (QINGDAO) Co.,Ltd. Address before: 266000 3601 Tuen Road, Qingdao economic and Technological Development Zone, Qingdao, Shandong Patentee before: Qingdao Zhengda Haier Pharmaceutical Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP03 | Change of name, title or address |
Address after: No.3601 Tuanjie Road, Qingdao Economic and Technological Development Zone, Shandong Province 266426 Patentee after: Qingdao Guoxin Pharmaceutical Co.,Ltd. Country or region after: China Address before: 266000 3601 Tuen Road, Qingdao economic and Technological Development Zone, Qingdao, Shandong Patentee before: CP PHARMACEUTICAL (QINGDAO) Co.,Ltd. Country or region before: China |
|
CP03 | Change of name, title or address |